Related Experiment Videos
Evaluation of a new polyamide membrane (Polyflux 130) in high-flux dialysis
R M Schaefer1, U Gilge, H Goehl
1Department of Medicine, University of Würzburg, FRG.
Abstract:
Removal of beta 2-microglobulin has become a major objective of dialysis therapy. The present study was performed to evaluate both compatibility and elimination capacity for beta 2-microglobulin of a newly developed high-flux polyamide membrane (Polyflux 130) during hemodialysis. The degree of leukopenia was moderate (-22%) and comparable with Polysulfone 600 (-25%). C3a desarg generation had a tendency to be lower with the Polyflux 130 membrane, and C5a desarg formation was identical with both types of membranes. As for degranulation of polymorphonuclear leukocytes, plasma elastase levels increased by 209% with Polyflux 130 and by 160% with Polysulfone 600 membranes. Likewise, plasma lactoferrin values rose during hemodialysis by 233% (Polyflux 130) and 160% (Polysulfone 600). The differences between membranes, however, were statistically not significant. There was a sharp drop in the serum levels of beta 2-microglobulin during dialysis with both membranes (Polyflux 130: -46%; Polysulfone 600: -48%). Accordingly, sieving coefficients were calculated to be 0.77 +/- 0.06 for Polyflux 130 and 0.80 +/- 0.06 for the Polysulfone 600 membrane. Both membranes were capable to remove large quantities of beta 2-microglobulin, amounting to 235 +/- 11 and 250 +/- 10 mg/4 h of dialysis for Polyflux 130 and Polysulfone 600, respectively.
Insights
The new Polyflux 130 hemodialysis membrane effectively removes beta 2-microglobulin, comparable to existing Polysulfone 600 membranes. Both membranes show good compatibility and elimination capacity for beta 2-microglobulin during dialysis.
Area of Science:
- Nephrology
- Biomaterials Science
- Biomedical Engineering
Background:
- Beta 2-microglobulin removal is a key goal in dialysis therapy.
- High-flux membranes are crucial for efficient solute removal during hemodialysis.
Purpose of the Study:
- To evaluate the compatibility and beta 2-microglobulin elimination capacity of a novel high-flux polyamide membrane (Polyflux 130).
- To compare the performance of Polyflux 130 with a Polysulfone 600 membrane in hemodialysis.
Main Methods:
- Hemodialysis using Polyflux 130 and Polysulfone 600 membranes.
- Monitoring of leukopenia, complement activation (C3a, C5a), polymorphonuclear leukocyte degranulation markers (elastase, lactoferrin).
- Measurement of serum beta 2-microglobulin levels and calculation of sieving coefficients.
Main Results:
- Both membranes demonstrated significant reduction in serum beta 2-microglobulin levels (-46% for Polyflux 130, -48% for Polysulfone 600).
- Sieving coefficients for beta 2-microglobulin were high for both membranes (0.77 for Polyflux 130, 0.80 for Polysulfone 600).
- Leukopenia and inflammatory marker changes were comparable between the two membranes, with no statistically significant differences.
Conclusions:
- The Polyflux 130 membrane exhibits excellent capacity for beta 2-microglobulin removal during hemodialysis.
- Polyflux 130 demonstrates comparable biocompatibility and solute removal efficiency to the Polysulfone 600 membrane.
- This new polyamide membrane is a viable option for enhancing beta 2-microglobulin clearance in dialysis patients.